Fyodor Bio is a pioneering biotech company focused on addressing critical global health challenges, particularly malaria. The company has developed the Urine Malaria Test (UMT), the first and only non-blood test that can diagnose malaria within minutes using a few drops of urine. This innovation aims to provide a quick, accurate, and convenient method for malaria diagnosis, reducing the risk of misdiagnosis and unnecessary medication. Fyodor Bio serves both individual consumers and healthcare providers, operating primarily in the global healthcare market. The company's business model includes direct sales through pharmacies and online platforms, as well as partnerships with medical institutions for broader distribution. Revenue is generated through the sale of UMT kits and potential collaborations with healthcare organizations.

Keywords: malaria diagnosis, urine test, biotech innovation, healthcare, non-blood test, rapid diagnosis, global health, medical research, consumer health, antimalarial treatment.